Harpoon Therapeutics Provides Pipeline Development Milestones for 2022

NEXT STORY
Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones
PREV STORY
Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis

Rockville, MD, Jan. 23, 2018 (GLOBE NEWSWIRE) -- --  MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage ...

author_avatar
NASDAQ Market News

Sanofi and Regeneron Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting

Sanofi and Regeneron Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College ...

author_avatar
NASDAQ Market News

Targovax ASA: First quarter 2017 results

Oslo, Norway, 25 April 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), ...

author_avatar
NASDAQ Market News